JSR will be providing the equity capital for OPM Asia that will enable the establishment of a world-class biomedical manufacturing and market development operation.
Crown Bioscience enhances its existing portfolio of humanized drug target models (HuGEMM™) by launching a new transgenic CD3E model to advance development of immuno-oncology (I/O) drugs.
Crown Bioscience announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the d...